FrancophonIA/ELRC3.0 huggingface dataset:
English: Grade 2 and Grade 3 cases were reported in 2.8% (7/248) and 1.6% (4/248) of patients, respectively.
Slovenian: O primerih stopnje 2 so poročali pri 2,8 % (7/248) bolnikov, o primerih stopnje 3 pa pri 1,6 % (4/248) bolnikov.
English: To be taken into consideration when treating patients on a controlled sodium diet.
Slovenian: To je treba upoštevati pri bolnikih, ki so na
English: Monitoring of adrenal function and hormone levels should continue to ensure appropriate corticosteroid replacement is utilised.
Slovenian: Za zagotovitev, da je zdravljenje z nadomeščanjem kortikosteroidov ustrezno, je treba kontinuirano nadzirati delovanje nadledvičnih žlez in vrednosti hormonov.
English: For symptomatic hypothyroidism, nivolumab should be withheld, and thyroid hormone replacement should be initiated as needed.
Slovenian: V primeru simptomatskega hipotiroidizma je treba zdravljenje z nivolumabom zadržati in po potrebi uvesti zdravljenje z nadomeščanjem ščitničnega hormona.
English: For symptomatic diabetes, nivolumab should be withheld, and insulin replacement should be initiated as needed.
Slovenian: V primeru simptomatske sladkorne bolezni je treba zdravljenje z nivolumabom zadržati in po potrebi uvesti zdravljenje z insulinom.
English: Nivolumab potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands.
Slovenian: Nivolumab prepreči vezavo ligandov PD-L1 in PD-L2 na receptor PD-1 in tako okrepi T-celični odziv, vključno s protitumorskim odzivom.
English: Grade 2 and Grade 3 cases were reported in 1.6% (4/248) and 0.8% (2/248) of patients, respectively.
Slovenian: O primerih stopnje 2 so poročali pri 1,6 % (4/248) bolnikov, o primerih stopnje 3 pa pri 0,8 % (2/248) bolnikov.
English: In CA209017 and CA209063, the incidence of liver function test abnormalities was 1.2% (3/248).
Slovenian: V študijah CA209017 in CA209063 je pojavnost nenormalnih izvidov delovanja jeter znašala 1,2 % (3/248).
English: Infections and infestations
Slovenian: nadledvičnih žlez in sladkorno boleznijo)
English: Grade 2 and Grade 3 cases were reported in 1.2% (3/248) and 0.4% (1/248) of patients, respectively.
Slovenian: O primerih stopnje 2 so poročali pri 1,2 % (3/248) bolnikov, o primerih stopnje 3 pa pri 0,4 % (1/248) bolnikov.
English: Monitoring of pituitary function and hormone levels should continue to ensure appropriate hormone replacement is utilised.
Slovenian: Za zagotovitev, da je zdravljenje z nadomeščanjem hormonov ustrezno, je treba kontinuirano nadzirati delovanje hipofize in vrednosti hormonov.
English: For Grade 3 or 4 pneumonitis, nivolumab must be permanently discontinued, and corticosteroids should be initiated at a dose of 2 to 4 mg/kg/day methylprednisolone equivalents.
Slovenian: V primeru pljučnice stopnje 3 ali 4 je treba zdravljenje z nivolumabom trajno ukiniti in uvesti zdravljenje s kortikosteroidi v odmerku, ki ustreza 2 do 4 mg/kg/dan metilprednizolona.
English: BRISTOL-MYERS SQUIBB, S.A.
Slovenian: Bristol-Myers Squibb Belgium S.A.
English: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Slovenian: Preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1. 4.4 Posebna opozorila in previdnostni ukrepi Uporaba nivolumaba je povezana s pojavom imunsko pogojenih neželenih učinkov.
English: Systemic immunosuppression
Slovenian: Imunsko pogojeni izpuščaj
English: Grade 2 and Grade 3 cases were reported in 2% (5/248) and 1.6% (4/248) of patients, respectively.
Slovenian: O primerih stopnje 2 so poročali pri 2 % (5/248) bolnikov, o primerih stopnje 3 pa pri 1,6 % (4/248) bolnikov.
English: Permanently discontinue Nivolumab BMS
Slovenian: Nivolumab BMS trajno ukinite.
English: For Grade 3 diarrhoea or colitis, nivolumab should be withheld and corticosteroids initiated at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents.
Slovenian: V primeru driske ali kolitisa stopnje 3 je treba zdravljenje z nivolumabom zadržati in uvesti zdravljenje s kortikosteroidi v odmerku, ki ustreza 1 do 2 mg/kg/dan metilprednizolona.
English: The total dose of Nivolumab BMS required can be infused directly as a 10 mg/mL solution or can be diluted to as low as 1 mg/mL with sodium chloride 9 mg/mL (0.9%) solution for injection or glucose 50 mg/mL (5%) solution for injection.
Slovenian: Celotni potrebni odmerek zdravila Nivolumab BMS se lahko infundira neposredno v obliki raztopine s koncentracijo 10 mg/ml ali pa se ga predhodno razredči do najnižje koncentracije 1 mg/ml z
English: Withhold Nivolumab BMS until laboratory values return to baseline and management with corticosteroids, if needed, is complete
Slovenian: zadržite dokler se laboratorijske vrednosti ne povrnejo do izhodiščnih vrednosti in zdravljenje s kortikosteroidi,
English: th
Slovenian: V
English: MARKETING AUTHORISATION HOLDER
Slovenian: ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
English: Three patients, including 2 patients with a Grade 3 case, received high-dose corticosteroids (at least 40 mg prednisone equivalents) at a median initial dose of 0.6 mg/kg (range: 0.4-1.3) for a median duration of 2.0 weeks (range: 1.4-14.1).
Slovenian: 40 mg prednizona) z medianim začetnim odmerkom 0,6 mg/kg (razpon: 0,4-1,3), zdravljenje pa je mediano trajalo 2,0 tedna (razpon: 1,4-14,1).
English: Severe diarrhoea or colitis has been observed with nivolumab treatment (see section 4.8).
Slovenian: Pri zdravljenju z nivolumabom so poročali o hudi driski ali kolitisu (glejte poglavje 4.8).
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Nivolumab BMS 10 mg/mL sterile concentrate nivolumab
Slovenian: Nivolumab BMS 10 mg/ml sterilni koncentrat
English: Underactive thyroid gland which can cause tiredness or weight gain Inflammation of the nerves causing numbness, weakness, tingling or burning pain of the arms and legs, headache, dizziness
Slovenian: Bolezni imunskega sistema občasni anafilaktična reakcija, preobčutljivost, reakcije, povezane z infundiranjem insuficienca nadledvičnih žlez, vnetje ščitnice periferna nevropatija, glavobol, omotica
English: For Grade 4 diarrhoea or colitis, nivolumab must be permanently discontinued, and corticosteroids should be initiated at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents.
Slovenian: V primeru driske ali kolitisa stopnje 4 je treba zdravljenje z nivolumabom trajno ukiniti in uvesti zdravljenje s kortikosteroidi v odmerku, ki ustreza 1 do 2 mg/kg/dan metilprednizolona.
English: Immune-related nephritis or renal dysfunction present with asymptomatic increases in serum creatinine.
Slovenian: Večina bolnikov je imela le asimptomatsko zvišano vrednost serumskega kreatinina.
English: STEP 1
Slovenian: KORAK
English: Check with your doctor or nurse before you are given Nivolumab BMS if: you have been told that your cancer has spread to your brain you have an autoimmune disease (a condition where the body attacks its own cells); you have any history of inflammation of the lungs; you have been taken medicines to suppress your immune system.
Slovenian: Preden boste prvič prejeli zdravilo Nivolumab BMS se posvetujte z zdravnikom ali medicinsko če vam je zdravnik povedal, da se je rak razširil v možgane.
English: Post-authorisation efficacy study (PAES): The MAH should submit an updated OS data for Study CA209017: a Phase 3, randomized study of nivolumab vs docetaxel in subjects with advanced or metastatic squamous NSCLC who have experienced disease progression during or after one prior platinum doublet-based chemotherapy regimen.
Slovenian: Študija učinkovitosti po pridobitvi dovoljenja za promet (PAES): Imetnik dovoljenja za promet z zdravilom mora predložiti dopolnjene podatke o celokupnem preživetju za študijo CA209017: randomizirana študija faze 3
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each mL of concentrate contains 10 mg of nivolumab.
Slovenian: En ml koncentrata vsebuje 10 mg nivolumaba.
English: Upon improvement, nivolumab may be resumed after corticosteroid taper, if needed.
Slovenian: Po izboljšanju in postopnem zmanjšanju odmerka kortikosteroida, če je bilo takšno zdravljenje potrebno, se zdravljenje z nivolumabom lahko nadaljuje.
English: Monitoring of thyroid function should continue to ensure appropriate hormone replacement is utilised.
Slovenian: Za zagotovitev, da je hormonsko nadomestno zdravljenje ustrezno, je treba kontinuirano
English: Grade 3 or 4 pneumonitis
Slovenian: NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN
English: Three patients, including the one patient with Grade 3 adrenal insufficiency, received high-dose corticosteroids (at least 40 mg prednisone equivalents) at a median initial dose of 1.1 mg/kg (range: 0.5-1.3) for 2.7 weeks (range: 0.6-4.6).
Slovenian: Trije bolniki, vključno z enim bolnikom z insuficienco nadledvičnih žlez stopnje 3, so prejemali visoke odmerke kortikosteroidov (odmerke, ki so ustrezali vsaj 40 mg prednizona) z medianim začetnim odmerkom
English: Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Slovenian: Vrednotenje tumorja na osnovi različice 1.1 kriterijev za vrednotenje odziva pri solidnih tumorjih (RECIST v1.1, Response Evaluation Criteria in Solid
English: Immune-related adverse reaction
Slovenian: Imunsko pogojeni neželeni učinek
English: Bristol-Myers Squibb B.V. Tel: + 31 (0)30 300 2222
Slovenian: Tel: + 31 (0)30 300 2222
English: Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment) Water for injections
Slovenian: polisorbat 80, natrijev hidroksid, klorovodikova kislina in voda za injekcije.
English: Common
Slovenian: Dogodki
English: More than one vial of Nivolumab BMS may be necessary to obtain the required dose.
Slovenian: Za potreben odmerek bo morda treba uporabiti več kot
English: After administration of the nivolumab dose, flush the line with sodium chloride 9 mg/mL (0.9%) solution for injection or 50 mg/mL (5%) glucose solution for injection.
Slovenian: 0,9-odstotno (9 mg/ml) raztopino natrijevega klorida za injiciranje ali s 5-odstotno (50 mg/ml)
English: No Grade 4 or 5 rash was reported in these studies.
Slovenian: izpuščaju stopnje 4 ali 5 v teh študijah niso poročali.
English: Bristol-Myers Squibb Gyógyszerkereskedelmi Kft. Tel: + 40 (0)21 272 16 00
Slovenian: Tel: + 40 (0)21 272 16 00
English: Nivolumab BMS should be continued in the presence of hormone replacement therapy a as long as no symptoms are present
Slovenian: Če med hormonskim nadomestnim zdravljenjem a simptomi niso prisotni, je treba zdravljenje z zdravilom Nivolumab BMS nadaljevati.
English: Gently mix the infusion by manual
Slovenian: Raztopino za infundiranje z vrtenjem v rokah nežno premešajte.
English: The patient takes one capsule one hour before starting each chemotherapy cycle.
Slovenian: Bolnik mora vzeti eno kapsulo eno uro pred začetkom vsakega cikla kemoterapije.
English: One of the active substances, palonosetron, has been authorised on its own in the EU since 2005.
Slovenian: Ena od zdravilnih učinkovin, palonosetron, je v EU samostojno odobrena od leta 2005.
English: The Committee therefore concluded that the medicine's benefits are greater than its risk and recommended that it be approved for use in the EU.
Slovenian: Odbor je zato zaključil, da so koristi zdravila večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Akynzeo on 27 May 2015
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Akynzeo, veljavno po vsej Evropski uniji, izdala 27. maja 2015.
English: The full EPAR and risk management plan summary for Akynzeo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Akynzeo sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Akynzeo.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Akynzeo.
English: What measures are being taken to ensure the safe and effective use of Akynzeo?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Akynzeo?
English: Other information about Akynzeo
Slovenian: Druge informacije o zdravilu Akynzeo
English: Akynzeo netupitant / palonosetron hydrochloride
Slovenian: Akynzeo netupitant/palonosetronijev klorid
English: This study involved 1,455 patients and the patients took dexamethasone, another medicine used to prevent vomiting, as an additional treatment.
Slovenian: V tej študiji je sodelovalo 1455 bolnikov, ki so kot dopolnilno zdravljenje prejemali tudi deksametazon, drugo zdravilo, ki se uporablja za preprečevanje bruhanja.
English: A risk management plan has been developed to ensure that Akynzeo is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Akynzeo je bil pripravljen načrt obvladovanja tveganj.
English: The most common side effects reported with Akynzeo are headache (seen in 3.6% of patients), constipation (3.0%) and fatigue (1.2%).
Slovenian: Najpogostejši neželeni učinki, o katerih so poročali pri uporabi zdravila Akynzeo, so glavobol (ki so ga opazili pri 3,6 % bolnikov), zaprtost (3,0 %) in utrujenost (1,2 %).
English: Akynzeo is available as capsules containing 300 mg of netupitant and 0.5 mg of palonosetron.
Slovenian: Zdravilo Akynzeo je na voljo v obliki kapsul, ki vsebujejo 300 mg netupitanta in 0,5 mg palonosetrona.
English: What benefits of Akynzeo have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Akynzeo izkazalo v študijah?
English: For more information about treatment with Akynzeo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Akynzeo preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: A second main study looked at the benefits of Akynzeo in patients undergoing moderately emetogenic chemotherapy.
Slovenian: V drugi glavni študiji so proučevali koristi zdravila Akynzeo pri bolnikih, ki prejemajo zmerno emetogeno kemoterapijo.
English: In a main study comparing Akynzeo with palonosetron alone, 90% of patients taking Akynzeo (121 out of 135) experienced no vomiting within 5 days of starting highly emetogenic chemotherapy compared with 77% of patients taking palonosetron alone (104 out of 136).
Slovenian: V glavni študiji, v kateri so zdravilo Akynzeo primerjali s samim palonosetronom, se bruhanje v 5 dneh po začetku zdravljenja z zelo emetogeno kemoterapijo ni pojavilo pri 90 % bolnikov, ki so jemali Akynzeo (121 od 135), v primerjavi s 77 % bolnikov, ki so jemali samo palonosetron (104 od 136).
English: Akynzeo is a medicine used to prevent nausea (feeling sick) and vomiting in adult patients with cancer who are receiving chemotherapy (medicines to treat cancer).
Slovenian: Akynzeo je zdravilo, ki se uporablja za preprečevanje navzeje (slabosti) in bruhanja pri odraslih bolnikih z rakom, ki prejemajo kemoterapijo (zdravila za zdravljenje raka).
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that Akynzeo was effective at preventing both the immediate and delayed phases of nausea and vomiting following chemotherapy, and that the medicine has a favourable safety profile.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je upošteval, da je zdravilo Akynzeo učinkovito preprečilo tako takojšnjo kot zapoznelo fazo slabosti in bruhanja po kemoterapiji in da ima ugoden varnostni profil.
English: What is Akynzeo and what is it used for?
Slovenian: Kaj je zdravilo Akynzeo in za kaj se uporablja?
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Akynzeo, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: What are the risks associated with Akynzeo?
Slovenian: Kakšna tveganja so povezana z zdravilom Akynzeo?
English: Some chemotherapy is known to induce severe nausea and vomiting, and Akynzeo is used in patients receiving either highly emetogenic (vomit-inducing) chemotherapy based on the cancer medicine cisplatin, or other chemotherapies that are moderately emetogenic.
Slovenian: Določene vrste kemoterapije dokazano povzročajo hudo slabost in bruhanje, zdravilo Akynzeo pa se uporablja pri bolnikih, ki prejemajo bodisi zelo emetogeno (takšno, ki povzroča bruhanje) kemoterapijo na osnovi zdravila proti raku cisplatina ali druge vrste kemoterapije, ki so zmerno emetogene.
English: For practical information about using Akynzeo, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Akynzeo naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Why is Akynzeo approved?
Slovenian: Zakaj je bilo zdravilo Akynzeo odobreno?
English: receptors, which are found in the nervous system and are responsible for the delayed phase of nausea and vomiting (that occurs after the first 24 hours); palonosetron, on the other hand, blocks 5HT3 receptors in the gut, which are responsible for the immediate phase (that occurs within the first 24 hours).
Slovenian: Netupitant deluje tako, da zavira receptorje za nevrokinin-1 (NK1) - receptorje, ki so prisotni v živčnem sistemu in so odgovorni za zapoznelo fazo slabosti in bruhanja (ki se pojavi po prvih 24 urah), palonosetron pa zavira receptorje 5HT3 v črevesju, ki so odgovorni za takojšnjo fazo (ki se pojavi v prvih 24 urah).
English: It is not intended to provide practical advice on how to use Akynzeo.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: Around 88% of patients taking Akynzeo experienced no vomiting on day 1 following the first chemotherapy cycle, compared with 85% of patients taking palonosetron.
Slovenian: Bruhanja prvi dan po prvem ciklusu kemoterapije niso opazili pri 88 % bolnikov, ki so jemali zdravilo Akynzeo, v primerjavi s 85 % bolnikov, ki so jemali palonosetron.
English: The figures for day 2 to day 5 were 77% for patients in the Akynzeo group and 70% for those in the palonosetron group.
Slovenian: Med drugim in petim dnem pa ga niso opazili pri 77 % bolnikov v skupini z zdravilom Akynzeo in pri 70 % bolnikov v skupini s palonosetronom.
English: The two active substances in Akynzeo work by blocking two different mechanisms involved in inducing nausea and vomiting during chemotherapy.
Slovenian: Zdravilni učinkovini v zdravilu Akynzeo delujeta tako, da zavirata dva različna mehanizma, ki sodelujeta pri povzročanju slabosti in bruhanja med kemoterapijo.
English: Akynzeo contains the active substances netupitant and palonosetron.
Slovenian: Zdravilo Akynzeo vsebuje zdravilni učinkovini netupitant in palonosetron.
English: How does Akynzeo work?
Slovenian: Kako zdravilo Akynzeo deluje?
English: How is Akynzeo used?
Slovenian: Kako se zdravilo Akynzeo uporablja?
English: By having both active substances together, Akynzeo helps provide control for both the immediate and delayed phases of nausea and vomiting than occur following chemotherapy.
Slovenian: Zdravilo Akynzeo, ki vsebuje obe zdravilni učinkovini, tako pomaga pri obvladovanju tako takojšnje kot zapoznele faze slabosti in bruhanja, ki se pojavita po kemoterapiji.
English: MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administra
Slovenian: (Izmišljeno) ime Jakost
English: Zona Industrial da Abrunheira - Edifício 10 - Sintra Business Park
Slovenian: Abrunheira - Edifício 10 - Sintra Business Park
English: Kruczkowskiego 8 00-380 Warzawa Poland
Slovenian: Kruczkowskiego 8 00-380 Warszawa Poland
English: 2710-089 Sintra Portugal
Slovenian: 2710-089 Sintra
English: Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states
Slovenian: PRILOGA I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVIL, POTI UPORABE, IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
English: Beriplast and associated names Member State (in EEA)
Slovenian: Beriplast in povezana imena Država članica (v EGP)
English: Artiss and associated names; Tisseel and associated names; Tissucol and associated names Member State (in EEA)
Slovenian: Artiss in povezana imena; Tisseel in povezana imena; Tissucol in povezana imena Država članica (v EGP)
English: Czech Republic Baxter Czech spol.
Slovenian: Baxter Czech spol.
English: Norfork IP24 3SE, United Kingdom
Slovenian: Norfolk IP24 3SE, United Kingdom
English: Baxter Médico-Farmacêutica, Lda.
Slovenian: Portugalska Baxter Médico-Farmacêutica, Lda.
English: The Netherlands Baxter AG Industriestraße 67
Slovenian: Nizozemska Baxter AG Industriestraße 67
English: Karla Engliše 3201/6
Slovenian: Karla Engliše 3201/6 150 00 Praha 5
English: BERIPLAST P 0.5 ml, 1 ml, 3 ml, powders and solvents for sealant Combi-Set
Slovenian: P 0.5 ml, 1 ml, 3 ml, powders and solvents for sealant
English: Baxter SA Boulevard René Branquart 80 7860 Lessines Belgium
Slovenian: Boulevard René Branquart 80 7860 Lessines
English: Combi-Set 2: thrombin: 500 IU/ml
Slovenian: Combi-Set 2: trombin : 500 IU/ml
English: ARTISS soluciones para adhesivo tisular
Slovenian: ARTISS soluciones para adhesivo tisular Ultracongeladas intralezijska uporaba
English: IU/ml
Slovenian: EIK2/ml
English: Baxter Medical AB, Isafjordstgatan 30B P.O.
Slovenian: Baxter Medical AB, Isafjordsgatan 30B P.O. Box 63
English: Intralesional use
Slovenian: Artiss intralezijska uporaba
English: Beriplast P CombiSet Pulver und Lösungsmittel für einen
Slovenian: Beriplast P Combi-Set Pulver und Lösungsmittel für einen Gewebekleber
English: Beriplast P CombiSet 0,5ml/1ml/3ml
Slovenian: Beriplast P Combi-Set 0,5ml/1ml/3ml
English: Tisseel - Lösungen für einen
Slovenian: Tisseel - Lösungen für einen Gewebekleber
English: Beriplast P CombiSet 1 ml prašek in vehikel za lepilo za tkiva
Slovenian: Combi-Set 1 ml prašek in vehikel za lepilo za tkiva
English: Beriplast P CombiSet 3 ml prašek in vehikel za lepilo za tkiva
Slovenian: Combi-Set 3 ml prašek in vehikel za lepilo za tkiva
English: Tisseel Lyo - Pulver und Lösungsmittel für einen
Slovenian: Tisseel Lyo - Pulver und Lösungsmittel für einen Gewebekleber
English: Norfork
Slovenian: Norfolk
English: ARTISS - Lösungen für einen
Slovenian: ARTISS - Lösungen für einen Gewebekleber
English: Thrombin: 500 IU/ml Calcium chloride: 5,9 mg/ml
Slovenian: Trombin : 500 IU/ml Kalcijev klorid: 5,9 mg/ml
English: Thrombin 1000 IU or Thrombin 8 UI; Calcium Chlorid Dihydrate 11.76 mg
Slovenian: 2. komponenta: trombin 1000 i.e. ali trombin 8 i.e.; kalcijev klorid dihidrat 11,76 mg
English: TISSUCOL Kit 1,0 kétkomponensű fibrinragasztó
Slovenian: Kit 1,0 kétkomponensű fibrinragasztó
English: Thrombin 2500 IU or Thrombin 20 UI; Calcium Chlorid Dihydrate 29.4 mg
Slovenian: 2. komponenta: trombin 2500 i.e. ali trombin 20 i.e.; kalcijev klorid dihidrat 29,4 mg
English: Fibrinogen human 90,00 mg /ml Factor XIII : 10,00 UI/ml Fibronectin : 5,50 mg/ml Plasminogen : 0,08 mg/ml Aprotinin 3000,0 UIK*** /ml
Slovenian: 1. komponenta: fibrinogen, humani 90,00 mg/ml faktor XIII: 10,00 i.e./ml fibronektin: 5,50 mg/ml plazminogen: 0,08 mg/ml aprotinin 3000,0 EIK***/ml
English: TISSUCOL Kit 2,0 kétkomponensű fibrinragasztó
Slovenian: Kit 2,0 kétkomponensű fibrinragasztó
English: 150 00 Praha 5
Slovenian: Tissucol Duo 500
English: Beriplast P CombiSet 0,5 ml, Beriplast P CombiSet 1 ml,
Slovenian: Beriplast P Combi-Set 0,5 ml, Beriplast P Combi-Set 1 ml, Beriplast P Combi-Set 3 ml
English: TISSUCOL Kit 5,0 kétkomponensű fibrinragasztó
Slovenian: Kit 5,0 kétkomponensű fibrinragasztó